Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Understanding the pharmacology of headache|
|Citation:||Current Opinion in Pharmacology, 2014; 14(1):30-33|
|Paul Edward Rolan|
|Abstract:||Migraine continues to be the most common of the debilitating headaches. Existing acute headache treatments are not always satisfactory, and current research is focussed on targeting neuroinflammatory pathways with drugs that are devoid of vascular action. Current prophylactic drugs are largely centred around antihypertensive, anticonvulsant and antidepressant drugs, although not all drugs of all sub-classes in these categories are effective. Selective agents which target the neuroinflammatory process including targets such as calcitonin gene related peptide, and PANNEXIN 1 may have clinical utility.|
|Keywords:||Animals; Humans; Headache; Calcitonin Gene-Related Peptide; Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Drug Design; Migraine Disorders; Molecular Targeted Therapy|
|Rights:||Copyright © 2013|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.